Compare Amylx Pharmaceuticals Inc (AMLX) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

MSTU trades at $1.87, down 1.06% with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% loss from November 2024 levels despite a 10:1 reverse stock split. Technical indicators show moving averages are unanimously bearish while oscillators remain neutral, with support and resistance clustered around $2.

The outlook remains challenging given the ETF's leveraged structure and substantial historical losses. Investment opportunity exists only for sophisticated traders comfortable with high volatility, while risks include daily rebalancing effects and continued erosion of value in declining markets. The fund's performance remains tightly coupled to its underlying asset's volatility.